REFERENCES
1. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
2. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20.
3. Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of obesity in adults: latest trends. Curr Obes Rep. 2018;7:276-88.
4. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904.
5. Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology. 2016;150:1798-810.
6. Chen Y, Du X, Kuppa A, et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet. 2023;55:1640-50.
7. Yuan Q, Wang H, Gao P, et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China. Int J Environ Res Public Health. 2022;19:2096.
8. Goldner D, Lavine JE. Nonalcoholic fatty liver disease in children: unique considerations and challenges. Gastroenterology. 2020;158:1967-83.e1.
9. Zong X, Kelishadi R, Hong YM, et al. Establishing international optimal cut-offs of waist-to-height ratio for predicting cardiometabolic risk in children and adolescents aged 6-18 years. BMC Med. 2023;21:442.
10. Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21:212.
11. Liu E, Li Q, Pan T, Chen Y. Association between secondhand smoke exposure and nonalcoholic fatty liver disease in the general U.S. adult nonsmoker population. Nicotine Tob Res. 2024;26:663-8.
12. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67:829-46.
13. Tsunoda K, Kitano N, Kai Y, Jindo T, Uchida K, Arao T. Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54:1330-9.
14. Ebrahimi F, Yao J, Hagström H, et al. Birth weight, gestational age, and risk of pediatric-onset MASLD. JAMA Netw Open. 2024;7:e2432420.
15. Querter I, Pauwels NS, De Bruyne R, et al. Maternal and perinatal risk factors for pediatric nonalcoholic fatty liver disease: a systematic review. Clin Gastroenterol Hepatol. 2022;20:740-55.
16. Wang X, Dang J, Liu J, et al. A cluster randomized trial of a comprehensive intervention nesting family and clinic into school centered implementation to reduce myopia and obesity among children and adolescents in Beijing, China: study protocol. BMC Public Health. 2023;23:1435.
17. Liu Y, Wang Y, Xing Y, et al. Establish a noninvasive model to screen metabolic dysfunction-associated steatotic liver disease in children aged 6-14 years in China and its applications in high-obesity-risk countries and regions. Lancet Reg Health West Pac. 2024;49:101150.
18. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954-61.
19. Flynn JT, Kaelber DC, Baker-Smith CM, et al; SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140(3):e20171904. Pediatrics. 2017;140:e20173035.
20. Chinese Society of Endocrinology CMA. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019). Chin J Endocrinol Metab. 2020;36:1-13. (in Chinese).
21. Committee on the Chinese Guidelines for Lipid Management. [Chinese guidelines for lipid management (2023)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023;51:221-55.
22. Care of Preterm or Low Birthweight Infants Group. Electronic address: [email protected]; Care of Preterm or Low Birthweight Infants Group. New WHO recommendations for the care of preterm or low birthweight infants have the potential to transform maternal and newborn health-care delivery. Lancet. 2022;400:1828-31.
23. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364-70.
24. prevention UScfdca. National Health and Nutrition Examination Survey. Available from: https://www.cdc.gov/nchs/nhanes/index.html. [Last accessed on 3 Sep 2025].
25. Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007;13:6419-24.
26. Yang S, Zhong J, Ye M, et al. Association between the non-HDL-cholesterol to HDL-cholesterol ratio and non-alcoholic fatty liver disease in Chinese children and adolescents: a large single-center cross-sectional study. Lipids Health Dis. 2020;19:242.
27. Li M, Shu W, Zunong J, et al. Predictors of non-alcoholic fatty liver disease in children. Pediatr Res. 2022;92:322-30.
28. Zhang X, Wan Y, Zhang S, et al. Nonalcoholic fatty liver disease prevalence in urban school-aged children and adolescents from the Yangtze River delta region: a cross-sectional study. Asia Pac J Clin Nutr. 2015;24:281-8.
29. Luo D, Ma N, Liu Y, et al. Long-term trends and urban-rural disparities in the physical growth of children and adolescents in China: an analysis of five national school surveys over three decades. Lancet Child Adolesc Health. 2023;7:762-72.
30. Dong Y, Lau PWC, Dong B, et al. Trends in physical fitness, growth, and nutritional status of Chinese children and adolescents: a retrospective analysis of 1·5 million students from six successive national surveys between 1985 and 2014. Lancet Child Adolesc Health. 2019;3:871-80.
31. Obita G, Alkhatib A. Disparities in the prevalence of childhood obesity-related comorbidities: a systematic review. Front Public Health. 2022;10:923744.
32. She D, Jiang S, Yuan S. Association between serum cotinine and hepatic steatosis and liver fibrosis in adolescent: a population-based study in the United States. Sci Rep. 2024;14:11424.
33. Quek SXZ, Tan EX, Ren YP, et al. Factors early in life associated with hepatic steatosis. World J Hepatol. 2022;14:1235-47.
34. Jiang X, Wu Y, Zhong H, et al. Human milk-derived extracellular vesicles alleviate high fat diet-induced non-alcoholic fatty liver disease in mice. Mol Biol Rep. 2023;50:2257-68.
35. Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by fibroscan. Clin Gastroenterol Hepatol. 2022;20:e1438-55.
36. Sun Q, Zhang T, Manji L, et al. Association between serum uric acid and non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Clin Epidemiol. 2023;15:683-93.
37. Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J Hepatol. 2023;78:1048-62.
38. Li Z, Kong Y, Chen S, et al. Independent and cumulative effects of risk factors associated with stillbirths in 50 low- and middle-income countries: a multi-country cross-sectional study. EClinicalMedicine. 2022;54:101706.
39. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082-90.
40. Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:61-71.e15.
41. Burra P, Zanetto A, Schnabl B, et al. Hepatic immune regulation and sex disparities. Nat Rev Gastroenterol Hepatol. 2024;21:869-84.
42. Burra P, Bizzaro D, Gonta A, et al; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41:1713-33.
43. Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. Focus on clinical aspects and implications for practice and translational research. J Clin Med. 2020;9:1278.
44. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457-69.
45. Suzuki A, Abdelmalek MF, Schwimmer JB, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Association between puberty and features of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:786-94.
46. Arnold AP, Klein SL, McCarthy MM, Mogil JS. Male-female comparisons are powerful in biomedical research - don’t abandon them. Nature. 2024;629:37-40.
